Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Default

Display 15 Products per page

Tybost
Read More
Tybost (cobicistat; Gilead) is a boosting agent to be used in combination with protease inhibitors (PIs) as part of treatment regimens for HIV-1 infection.
December 11, 2015
Find out more
U.S. Markets for Drug and Fluid Delivery Devices

$5,250.00

Pharmacotherapy represents the first-line treatment in the management of most chronic and transient medical conditions warranting therapeutic intervention in the U.S.
December 1, 2015
Find out more
Global Spinal Implants Market

$5,250.00

Spine disorders are a leading driver of healthcare costs worldwide, and range in severity from mild pain and loss of feeling to extreme pain and paralysis. These disorders are primarily caused by degenerative conditions in the spine, deformity, tumors and trauma.
December 1, 2015
Find out more
U.S. Markets for Minimally Invasive Benign Prostatic Hyperplasia and Prostatitis Therapies

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunites in the benign uterine condition therapy systems market, including global endometrial ablation systems, MR-guided focused ultrasound systems, uterine artery embolization systems, and hysteroscopes/fibroid removal systems.
November 14, 2015
Find out more
Treatment of VTE – EU KOL Interview

$599.00

This interview with an EU vascular physician explores the dynamics in the 5 major European markets regarding the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.
November 4, 2015
Find out more
Treatment of VTE – US KOL Interview

$599.00

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.
November 2, 2015
Find out more
U.S. Patient Monitoring Devices Market, November 2015

$5,250.00

This report provides a summary of the nearly $2 billion U.S. patient monitoring devices market.
November 2, 2015
Find out more
U.S. Surgical Procedure Volumes

$4,750.00

This report presents the most common surgical procedures performed in the United States (U.S.) as well as an overview of the etiology and epidemiology of selected diseases/disorders, prevailing surgical approaches/techniques, and evolving procedural utilization trends.
November 1, 2015
Find out more
2015 Jardiance EMPA-REG CVOT Pulse

$599.00

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).
November 1, 2015
Find out more
Recentin
Read More
Recentin (cediranib; AstraZeneca) is a small molecule inhibitor of all three vascular endothelial growth factor receptor (VEGFR-1, -2, -3) tyrosine kinases.
October 30, 2015
Find out more
Vigil
Read More
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
October 30, 2015
Find out more
ChimeriVax-Dengue
Read More
ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs.
October 28, 2015
Find out more
Biosimilars Market Access in the US

$2,995.00

This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.
October 23, 2015
Find out more
Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.
October 21, 2015
Find out more
Malignant Melanoma Pricing, Reimbursement and Access

$2,995.00

This strategy report focuses on Malignant Melanoma Pricing and Reimbursement including how immunotherapies are changing melanoma treatment paradigms with market conext in the US, Japan, and five major EU markets.
September 30, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *